Biomerica (BMRA) AI Stock Analysis

• Market Cap: $9.41M
• Dividend Yield: N/A
• Average Volume (3M): 187.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: 1.39%
• EPS Growth: 13.89%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 70
• Industry: Medical - Devices
• EPS (TTM): -0.33
• Shares Outstanding: 18,336,994
• 10 Day Avg. Volume: 151,297
• 30 Day Avg. Volume: 187,236
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.25
• Price to Cash Flow (P/CF): -4.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Biomerica's stock score is primarily impacted by its financial struggles, including persistent losses and negative cash flows. The technical analysis provides mixed signals, with a hint of bullish momentum overshadowed by an overbought RSI. Valuation concerns, highlighted by a negative P/E ratio, further contribute to the low score.

Biomerica Business Overview & Revenue Model

Company Description

Biomerica, Inc. (BMRA) is a global biomedical technology company that specializes in the development, manufacturing, and marketing of diagnostic products. Operating primarily in the healthcare sector, Biomerica focuses on providing innovative solutions for the early detection and monitoring of chronic diseases. Their core products include diagnostic tests for gastrointestinal diseases, food intolerances, diabetes, and other medical conditions, distributed to hospitals, laboratories, and physicians' offices worldwide.

How the Company Makes Money

Biomerica, Inc. generates revenue through the sale of its diagnostic products. The company's revenue model primarily relies on the production and distribution of diagnostic tests that are used in medical settings. Key revenue streams include sales to hospitals, clinical laboratories, and healthcare providers who utilize these tests for patient care. Additionally, Biomerica engages in partnerships and collaborations with other healthcare companies and research institutions, which can also contribute to its earnings. The company's focus on innovation and expanding its product offerings allows it to tap into new markets and increase its revenue potential.

Biomerica Financial Statement Overview

Summary

Biomerica faces substantial financial challenges with continuous losses, weak revenue growth, and negative cash flows. Despite a strong equity position, operational inefficiencies and poor cash generation pose significant risks.

Income Statement

Biomerica's income statement shows persistent challenges with profitability and revenue growth. The gross profit margin for the TTM period is approximately 10.7%, indicating low profitability from its core operations. The net profit margin is negative, reflecting ongoing losses. Revenue growth is sluggish, with a slight improvement of 3% over the previous annual period. The company faces significant EBIT and EBITDA losses, reflecting operational inefficiencies.

Balance Sheet

The balance sheet reflects a moderate financial position with a debt-to-equity ratio of approximately 0.12, suggesting low leverage. However, the return on equity is negative, showing a lack of profitability. The equity ratio stands at 70.3%, indicating a strong equity base compared to total assets, which provides some cushion against liabilities.

Cash Flow

Biomerica's cash flow statement highlights significant challenges in cash generation. The operating cash flow to net income ratio is negative, indicating poor operating performance. Free cash flow is consistently negative, and there is no free cash flow growth, showing inadequate cash flow to cover capital expenditures and other investments.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
5.58M	5.42M	5.34M	18.87M	7.20M	6.69M
	Gross Profit
597.00K	611.00K	446.00K	2.98M	496.98K	1.78M
	EBIT
-5.89M	-6.37M	-7.22M	-4.53M	-6.52M	-2.40M
	EBITDA
-5.49M	-5.99M	-6.74M	-3.94M	-7.06M	-2.27M
	Net Income Common Stockholders
-5.61M	-5.98M	-7.14M	-4.53M	-6.47M	-2.34M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.13M	4.17M	9.72M	5.92M	4.20M	8.64M
	Total Assets
5.12M	9.25M	14.45M	11.37M	11.82M	17.26M
	Total Debt
91.34K	785.00K	1.08M	1.38M	1.62M	1.78M
	Net Debt
-1.04M	-3.38M	-8.64M	-4.54M	-2.58M	-6.86M
	Total Liabilities
896.37K	2.66M	2.73M	3.05M	2.59M	3.05M
	Stockholders Equity
4.22M	6.59M	11.72M	8.32M	9.23M	14.21M
Cash Flow		Free Cash Flow
-5.02M	-5.48M	-5.55M	-650.87K	-5.55M	-4.42M
	Operating Cash Flow
-4.98M	-5.36M	-5.47M	-480.53K	-5.25M	-4.30M
	Investing Cash Flow
-73.00K	-115.00K	-78.00K	-170.34K	-295.58K	-118.93K
	Financing Cash Flow
299.00K	-81.00K	9.39M	2.39M	1.11M	12.37M

Biomerica Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.54
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Neutral. The current price of 0.54 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.65, and above the 200-day MA of 0.44, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.24 is Neutral, neither overbought nor oversold. The STOCH value of 6.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMRA.

Biomerica Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	68 Neutral	$1.02B	18.49	19.46%	―	19.07%	―
OSUR	52 Neutral	$227.82M	25.27	-4.64%	―	-54.17%	-135.78%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
BMRA	45 Neutral	$9.41M	―	-77.33%	―	1.39%	13.89%
QDEL	45 Neutral	$1.95B	―	-50.74%	―	-7.03%	-20233.78%
TTOO	35 Underperform	$3.37M	―	366.81%	―	-30.19%	97.74%
AXDX	33 Underperform	$14.62M	―	110.26%	―	-2.99%	59.87%